Virtus Advisers LLC Invests $425,000 in Organogenesis $ORGO

Key Points

• Virtus Advisers LLC has acquired a new position in Organogenesis, purchasing 98,381 shares valued at approximately $425,000, representing about 0.08% of the company.
• Several institutional investors, including Wealth Enhancement Advisory Services and Millennium Management, have increased their stakes in Organogenesis during the first quarter and fourth quarter.
• Analysts have a consensus rating of "Moderate Buy" on Organogenesis, with Cantor Fitzgerald raising its price target from $7.00 to $9.00.

Virtus Advisers LLC purchased a new stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 98,381 shares of the company's stock, valued at approximately $425,000. Virtus Advisers LLC owned about 0.08% of Organogenesis at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Organogenesis by 10.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock valued at $187,000 after purchasing an additional 4,239 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Organogenesis by 29.6% in the fourth quarter. Wells Fargo & Company MN now owns 41,471 shares of the company's stock valued at $133,000 after purchasing an additional 9,464 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Organogenesis by 18.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock valued at $8,925,000 after purchasing an additional 442,772 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Organogenesis by 53.2% in the fourth quarter. Squarepoint Ops LLC now owns 126,791 shares of the company's stock valued at $406,000 after purchasing an additional 44,051 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Organogenesis by 255.1% in the fourth quarter. Mackenzie Financial Corp now owns 76,353 shares of the company's stock valued at $244,000 after purchasing an additional 54,850 shares in the last quarter. Institutional investors and hedge funds own 49.57% of the company's stock.

Organogenesis Stock Up 0.6%

NASDAQ ORGO traded up $0.03 on Friday, hitting $5.15. 314,198 shares of the stock were exchanged, compared to its average volume of 712,810. Organogenesis has a fifty-two week low of $2.45 and a fifty-two week high of $6.71. The company has a market cap of $653.33 million, a PE ratio of -36.78 and a beta of 1.76. The company has a 50-day moving average price of $4.47 and a 200-day moving average price of $4.18.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Organogenesis had a negative return on equity of 0.37% and a negative net margin of 1.92%.The firm had revenue of $101.01 million for the quarter, compared to analyst estimates of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Organogenesis will post -0.07 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Lori Freedman purchased 142,379 shares of the stock in a transaction on Thursday, June 5th. The stock was bought at an average price of $2.91 per share, for a total transaction of $414,322.89. Following the acquisition, the insider directly owned 837,437 shares of the company's stock, valued at approximately $2,436,941.67. The trade was a 20.48% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders have purchased 252,264 shares of company stock worth $725,732. Insiders own 33.00% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on ORGO shares. Cantor Fitzgerald lifted their price objective on shares of Organogenesis from $7.00 to $9.00 and gave the company an "overweight" rating in a report on Friday, August 8th. BTIG Research restated a "buy" rating on shares of Organogenesis in a report on Tuesday, July 15th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.